[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NHS Greater Glasgow and Clyde\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":683},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,43,72,100,130,171,199,220,249,281,309,331,354,380,406,428,453,478,498,524,547,568,594,634,653],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100621583","glasgow-low-dose-ct-and-ai-based-diagnostics-to-case-find-lung-cancer-and-other-cardio-respiratory-long-term-conditions---feasibility-study-100621583",false,"NCT07372508","Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study","GALACTIC 1 - Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study","GALACTIC-1","Inclusion Criteria:\n\n* Resident in South Sector NHS GG\\&C.\n* Capacity to undertake informed consent.\n* No active cancer other than non-melanoma skin cancer, monitored localised prostate cancer or localised treated breast cancer.\n* Aged 55-74 at date of invitation.\n* Smoking history: current tobacco smoker or ex-smoker with \\>20 pack year history and \\\u003C15 years from quit date.\n\nExclusion Criteria:\n\n* CT thorax scan undertaken in prior 12 months.\n* Does not have capacity to give consent (standard criteria for assessing capacity apply).\n* Aged \\\u003C55 or \\>74 years of age at date of invitation\n* Weight exceeds restrictions for scanner (\\>200kg).\n* Unable to lie flat.\n* People who are pregnant.\n* Active symptoms of possible lung cancer","ALL","55 Years","74 Years",{"count":22,"type":23},500,"ESTIMATED","INTERVENTIONAL",[26],"NA","Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates. The value of screening for lung cancer with low-dose CT (LDCT) scans has been established, and these scans can also identify other diagnoses earlier.\n\nAdditional tests undertaken alongside the CT scan may add value to the lung cancer screening program being rolled out. This study aims to explore the feasibility and utility of a lung cancer screening program with added heart and breathing tests within a single clinic visit.\n\nA Lung Health Check will be offered to people at higher risk of lung cancer, specifically those aged 55-74 with a history of cigarette smoking. This will include a quick and painless LDCT scan, which uses a small amount of radiation to create detailed images of the lungs to detect lung cancer at an early and more treatable stage.\n\nIn this \"GALACTIC-1\" study, the investigators will explore whether structured reporting of the CT scan, combined with additional tests (blood sample, ECG heart trace, and spirometry breathing test), can help identify conditions such as chronic obstructive pulmonary disease (COPD), lung scarring (pulmonary fibrosis), coronary artery disease, heart failure, and early signs of bone fractures (osteoporosis). This enhanced Lung Health Check may improve overall health by identifying and allowing early management of these conditions.\n\nThe investigators plan to use the data from the \"GALACTIC-1\" study to explore AI performance by comparing it to reporting done by doctors. The results will help shape future rollout of lung cancer screening across Scotland, ensuring it is effective, efficient, and beneficial.\n\nThe investigators will also have a focus group with patients and interviews with NHS staff to understand their opinions on the screening.",[29],"Cancer","RECRUITING","2026-06-18",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2026-05-26",{"date":38,"type":23},"2028-09-02",{"name":40,"class":41},"NHS Greater Glasgow and Clyde","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100623026","strategy-for-early-recognition-of-cancer-copd--heart-failure-in-the-emergency-department-100623026","NCT07391280","Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department","SEARCH-ED","Inclusion Criteria:\n\nUnconsented Use of Harrison CXR Algorithm in Emergency Department (ED):\n\n* Frontal Chest X-Ray (CXR) (AP or PA) acquired in the Queen Elizabeth University Hospital (QEUH) ED\n* Patients aged 18 or over\n* Appropriate meta data (DICOM) to allow for Harrison CXR processing and secondary capture report provision.\n\nPatient Focus Groups:\n\n* Aged 18 or over\n* Able to provide written, informed consent in English.\n\nClinician Focus Groups:\n\n* Aged 18 or over\n* Able to provide written, informed consent in English.\n* Working as a doctor, advanced nurse practitioner or advanced clinical practitioner in ED, radiology or downstream medical specialties\n* For post-implementation focus groups only, must have at least 4 months experience of working with Harrison CXR algorithm.\n\nDiagnostic Clinic:\n\n* Patients without terminal illness or advanced frailty\n* Usual healthcare provider based in NHS GGC\n\nExclusion Criteria:\n\nApplies to use of unconsented CXRs:\n\n\\- Patient has requested that they are removed from the study, or has objected to the use of AI in their routine clinical care and this has been subsequently upheld by the health board.\n\nApplies to invitation to combined diagnostic clinic:\n\n* Patients not available to follow up, including patients i.e. whose the patient's usual care (or onward care following index admission) is out-with NHS GGC.\n* Patients who have been referred to palliative care for end-stage disease, or patients with severe frailty (i.e. bedbound) will not be invited to the combined diagnostic clinic\n\nFor Patient and Clinician Focus Groups:\n\n* Unable to provide informed written consent in English\n* Aged \\\u003C18","18 Years",{"count":52,"type":23},17000,[26],"SEARCH-ED is a research study which is running in Emergency Department (ED) of the Queen Elizabeth University Hospital. The aim of the study is to find out if using a computer programme can help doctors diagnose heart and lung problems from chest x-rays.\n\nWe want to compare how many people are diagnosed with heart or lung problems for the first time when doctors have access to the computer programme results, in comparison to when they don't.",[29,56,57],"Cardiovascular","Respiratory",[59,60,61,62,63],"Artificial Intelligence","Chest X-Ray","Lung Cancer","Heart Failure","COPD","2026-05-28",{"date":66,"type":34},"2026-06-01",{"date":68,"type":34},"2026-05-25",{"date":70,"type":23},"2027-06",{"name":40,"class":41},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100627078","combination-of-biologic-and-anti-obesity-therapies-in-psoriatic-arthritis-100627078","NCT07443956","Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","COMBAT-PsA","Inclusion Criteria:\n\n1. Age \\>= 18 years and \\\u003C=75 years\n2. Have a documented diagnosis of PsA for at least 6 months AND fulfil the CASPAR criteria (Defined as \\>=3 points)\n3. Have active PsA defined as \\>=3 swollen and \\>=3 tender joints (dactylitis counts as a swollen joint).\n4. Have a BMI \\>= 27 kg\u002Fm\\^2\n5. Have at least one affected joint amenable to ultrasound-guided synovial biopsy (and must undergo successful synovial biopsy prior to randomisation)\n6. Have at least one psoriatic plaque amenable to biopsy (up to a maximum of 5 participants per treatment arm can be recruited without skin biopsy if no suitable lesion\n7. Capable of giving signed informed consent\n8. Willing and able to participate in the study and undergo synovial, adipose and skin (if appropriate) biopsies (under local anaesthetic) on at least 2 occasions\n\nExclusion Criteria:\n\nPrior\u002FConcomitant Therapy:\n\n1. Previous treatment with tirzepatide or any GLP-1 receptor agonist.\n2. Previous treatment with Ixekizumab.\n3. Previous treatment with BOTH secukinumab AND Bimekizumab. \\[note: Previous treatment with one of EITHER secukinumab OR Bimekizumab for PsA\u002Fpsoriasis is allowed PROVIDED: i) Last dose was \\>6months before baseline AND ii) Therapy was not stopped due to an IL-17-related side effect OR due to complete primary lack of response.\n4. Previous treatment with rituximab.\n5. Failed \\>3 classes of advanced therapies (regardless of given for PsA or psoriasis), including but not limited to:\n\n   * TNF inhibitors (adalimumab, etanercept, certolizumab, golimumab, and infliximab)\n   * IL-12\u002F23 inhibitors (ustekinumab)\n   * IL-23 inhibitors (guselkumab and risankizumab)\n   * IL-17 Inhibitors (secukinumab or bimekizumab)\n   * Selective co-stimulation modulators (abatacept)\n   * Janus Kinase or tyrosine kinase 2 inhibitors (tofacitinib, upadacitinib and deucravacitinib) Note: Prior exposure to phosphodiesterase-4 inhibitors, such as apremilast and conventional synthetic DMARDs, such as methotrexate, are not considered as advanced therapies.\n6. If currently receiving conventional DMARDs, or apremilast, must have been treated for at least 12 weeks prior to first biopsy visit and on a stable dose for at least 8 weeks prior to first biopsy visit.\n7. Use or oral, intra-articular, IM or IV corticosteroids 4 weeks prior to first biopsy visit or anticipated\u002Fplanned prior to the week 12 biopsy visit.\n8. Topical steroids within 2 weeks of first biopsy visit (participants on topical corticosteroids at baseline willing to leave these off 2 weeks prior to biopsy will be eligible).\n9. Live, attenuated or recombinant vaccination within 1 month prior to screening visit or planned before the 12 week visit.\n10. Contraindication to local anaesthetics (lidocaine\u002Fsimilar) used for biopsies\n11. Antiplatelet or anticoagulant therapy that cannot be safely interrupted:\n\n    1. Clopidogrel or other antiplatelet therapies (note: aspirin is not an exclusion)\n    2. Vitamin K antagonists (including but not limited to warfarin)\n    3. Direct inhibitors of thrombin (e.g. dabigatran)\n    4. Factor Xa inhibitors (e.g. rivaroxaban, apixaban)\n    5. Heparins (including low-molecular weight heparins (LMWH)\n12. Previous treatment with insulin (exception: Use of insulin for gestational diabetes or short-term use (less than 14 days) for acute conditions, such as acute illness, hospitalisation or elective surgery).\n\n    Medical Conditions:\n13. Diagnosis of type 1 diabetes or insulin treated type 2 diabetes.\n14. History of severe hypoglycaemia and\u002For hypoglycaemia unawareness within the 6 months prior to screening.\n15. History of ketoacidosis or hyperosmolar state or coma in the last year\n16. Any current or past diagnosis of:\n\n    * proliferative diabetic retinopathy, or\n    * diabetic maculopathy, or\n    * non-proliferative diabetic retinopathy that requires treatment.\n17. Have a self-reported change in body weight greater than 5% (gain or loss) within 3 months prior to screening.\n18. Prior or planned surgical treatment for obesity, such as gastric bypass (bariatric) surgery or restrictive bariatric surgery (excluding liposuction or abdominoplasty if performed more than 1 year prior to screening).\n19. Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2.\n20. History of IBD (Crohn's disease or ulcerative colitis).\n21. Known clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction); or chronically take drugs that directly effect gastroparesis.\n22. History of chronic or acute pancreatitis.\n23. Renal Impairment with estimated glomerular filtration rate (GFR) of less than or equal to 30ml\u002Fmin\u002F1.73m\\^2.\n24. A diagnosis or history of malignant disease within 5 years prior to baseline visit, with the following exceptions:\n\n    * Basal cell and squamous epithelial carcinomas of the skin that have been resected, with no evidence of metastatic disease for 3 years and 2 years, respectively.\n    * cervical carcinoma in situ, with no evidence of recurrence within 3 years.\n25. History of any other condition (such as known drug, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, may preclude the participant from following and completing the study.\n26. History of significant active or unstable major depressive disorder (MDD), suicidal ideation, or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years.\n\n    Note: Participants with MDD or generalised anxiety disorder whose disease state is considered stable for the past year and expected to remain stable throughout the course of the study, in the opinion of the investigator, may be considered for inclusion if they are not on excluded medications.\n27. Are, in the judgement of the investigator, actively suicidal or deemed to be at significant risk for suicide.\n28. Diagnosis of other inflammatory arthritis, such as rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, gout, or enteropathic arthritis.\n29. Active infection at screening.\n30. Have had any of the following types of infection within 3 months prior to screening or develops any of the following infections before the baseline visit:\n\n    * Serious (requiring hospitalisation, or intravenous or equivalent oral antibiotic treatment, or both).\n    * Opportunistic. Note: Herpes Zoster is considered active and ongoing until all vesicles are dry and crusted over).\n    * Chronic (duration of symptoms, signs and\u002For treatment of 6 weeks or longer).\n    * recurring (including, but not limited to, herpes simplex, herpes zoster, recurring cellulitis, and chronic osteomyelitis).\n31. Have evidence or suspicion of active or latent TB (unless screened previously, all will be evaluated for TB prior to initiating treatment) or had latent TB infection that has not been treated with a complete course of appropriate therapy as per local guidelines, unless such therapy is currently underway.\n32. Current HIV infection.\n33. Current infection with hepatitis B virus (HBV) (i.e. positive for HBsAg and\u002For PCR positive for HBV DNA).\n34. Current infection with hepatitis C virus (HCV) (i.e. positive for HCV RNA).\n35. History of recurrent or chronic infection which in the opinion of the investigator might place a participant at unacceptable risk for participation in the study.\n36. Major surgery witing 8 weeks prior to screening or planned within 12 weeks from baseline visit.\n37. Any other condition that is a contraindication to ixekizumab or tirzepatide.\n\n    Laboratory results:\n38. If type 2 diabetic, laboratory evidence of poorly controlled diabetes, including HbA1c \\>80mmol\u002Fmol (\\>9.5%).\n39. Clinical laboratory test results at screening that are outside the normal reference range for the population and are considered clinically significant, or have any of the following specific abnormalities:\n\n    * Absolute neutrophil count \\\u003C1.5 x 10\\^3\u002Fmicrolitre\n    * Lymphocyte count \\\u003C0.80 x 10\\^3\u002Fmicrolitre\n    * Platelet count \\\u003C100 x 10\\^3\u002Fmicrolitre\n    * Total WBC count \\\u003C3.00 x 10\\^3\u002Fmicrolitre\n    * Haemoglobin \\\u003C85 g\u002FL (males) or \\\u003C80g\u002FL (females)\n    * AST or ALT levels \\>3 x upper limit of local normal range\n    * Serum creatinine levels \\>2.0omg\u002FdL (equivalent to \\>176.8 micromol\u002FL Participants who fail screening as a result of a minor blood test abnormality\u002Fabnormalities may be re-screened and have the test(s) repeated, within 14 days of the previous blood test, at the investigators discretion. If the tests meet the trial entry criteria on the second occasion, then the participant will be deemed to meet the entry criteria for the trial.\n\n    In women of child bearing potential(WOCBP):\n40. Are Pregnant, breastfeeding or planning to become pregnant during the course of the study.\n41. Not established, or unwilling to use a method of contraception considered highly effective for the duration of the study and at least 4 weeks after the study if they receive tirzepatide, or 10 weeks if they receive ixekizumab. Tirzepatide may decrease the effectiveness of oral contraceptives, so it is advised that WOCBP using an oral contraceptive should add a barrier method of contraception or switch to a non-oral contraceptive method for the first 4 weeks of treatment, and for 4 weeks after each dose increase.\n\n    Other exclusions:\n42. Have participated, within the last 30 days prior to trial entry, in a clinical study involving an investigational study intervention. If the previous investigational study intervention has a long half life, then 5 half lives or 30 days (whichever is longer), should have passed prior to screening.\n43. Are currently enrolled in any other clinical study involving an investigational study intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.\n44. Unable or unwilling to provide informed consent.\n45. Are unsuitable for inclusion in the study, in the opinion of the investigator or sponsor, for any reason that may compromise the participant's safety or confound data interpretation.\n46. Any other contra-indications to biopsies (including anti-coagulants) in the opinion of the investigator.","75 Years",{"count":81,"type":23},45,[26],"This is a trial to find out how weight loss (achieved by the use of tirzepatide) or ixekizumab treatment affects the characteristics of skin, joint and fat tissues in patients with Psoriatic Arthritis, Psoriasis and obesity\u002Foverweight BMI \\>=27.\n\nParticipants will be allocated either Tirzepatide, Ixekizumab or both. Samples of joint tissue, fat and skin will be taken at the start of the study and week 12. Blood and urine samples will also be taken.\n\nThe primary objective will be to assess the changes seen in the joint, fat and skin tissue samples 12 weeks after starting the medications (additional analysis will be done on the optional 36 week samples).\n\nSecondary objectives will be\n\n* To assess the changes seen in blood 4, 12, 36 and 52 weeks after starting the medication.\n* To compare the changes seen in tissue and blood between Ixekizumab and Tirzepatide\u002FWeight loss.\n* To see how the changes seen in the tissue relate to weight loss.",[85,86],"Psoriatic Arthritis (PsA)","Obesity & Overweight",[88,89,90],"Psoriatic Arthritis","Obesity","PsA","2026-04-28",{"date":93,"type":34},"2026-05-04",{"date":95,"type":34},"2026-03-09",{"date":97,"type":23},"2030-05",{"name":40,"class":41},4,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100585854","pre-emptive-pharmacogenomics-in-acute-care-settings-with-health-economic-evaluations-phoenix-trial-100585854","NCT06907784","PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)","PHOENIX TRIAL - A PILOT RANDOMISED CONTROLLED TRIAL OF PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS","PHOENIX","Inclusion Criteria INPATIENTS Age ≥18 years\n\n* Capable of giving informed consent directly or via a legal representative (e.g., next of kin, welfare guardian, health care power of attorney).\n* Participants who are newly prescribed one of the trial-eligible index drugs during their hospital stay may be approached for consent. Consent should be obtained within 3 days of the first dose of the index drug being administered. If there is a clear clinical plan documented on HEPMA indicating that the patient will be started on an eligible drug (but has not yet received the first dose), consent may be obtained in anticipation. However, formal trial enrolment will only occur once the first dose of the index drug has been administered.\n* Participant is able to provide a cheek swab\n* Participant is able to take part and be followed-up for at least 12 weeks.\n* Participant is resident in NHSGGC health board area OUTPATIENTS\n* Age ≥18 years\n* Capable of giving informed consent directly or via a legal representative (e.g., next of kin, welfare guardian, health care power of attorney).\n* Participants who are expected to be prescribed a trial-eligible drug during their outpatient clinic visit may be approached for consent prior to starting the medication. In these cases, formal trial enrolment will only occur once the patient has confirmed that they have received and started the prescribed medication\n* Participant must not have a prescription for this drug in the previous 3 months.\n* Participant is able to provide a cheek swab\n* Participant is able to take part and be followed-up for at least 12 weeks.\n* Participant is resident in NHSGGC health board area.\n\nExclusion Criteria INPATIENTS\n\n* Inability to give informed consent directly or via a legal representative.\n* Non-English speakers without translation support.\n* Participants co-enrolled in other trials where a medication is one of the index drug is part of the trial protocol.\n* Inability to give informed consent directly or via a legal representative.\n* Non-English speakers without translation support.\n* Participants co-enrolled in other trials where a medication is one of the index drug is part of the trial protocol.\n* Life expectancy estimated to be less than 6 months by treating clinical team.\n* Severe illness limiting participation (investigator discretion).\n* Duration of index drug total treatment length is planned to be less than five consecutive days.\n* Not registered with a General Practitioner.\n* No fixed address.\n* Participant is, in the opinion of the Investigator, not suitable to participate in the trial.\n* Participant has existing impaired hepatic or renal function for which a lower dose of the index drug or alternate selection of the index drug is already part of current routine care.\n* Estimated glomerular filtration rate greater than 15 ml\u002Fmin\u002F1.73m2 (except for participants with a renal transplant commenced on tacrolimus, who may be included regardless of eGFR, provided they are not on dialysis).eGFR result obtained at screening or within the last 6 months or patients record confirming history of CKD 5\n* Participants on any form of dialysis.\n* Participant with advanced liver failure (stage Child-Pugh C).\n* Participants with liver transplant.\n* Participants with allogeneic haematopoietic stem cell transplant.\n* Participants previously enrolled in the PHOENIX trial.\n* Participant who has declined participation and has declined reapproach for subsequent drugs.\n* Index drug exceeding trial drug cap. OUTPATIENTS\n* Inability to give informed consent directly or via a legal representative.\n* Non-English speakers without translation support.\n* Participants co-enrolled in other trials where a medication is one of the index drug is part of the trial protocol.\n* Life expectancy estimated to be less than 6 months by treating clinical team.\n* Severe illness limiting participation (investigator discretion).\n* Duration of index drug total treatment length is planned to be less than seven consecutive days.\n* Not registered with a General Practitioner.\n* No fixed address.\n* Participant is, in the opinion of the Investigator, not suitable to participate in the trial.\n* Participant has existing impaired hepatic or renal function for which a lower dose or alternate drug selection is already part of current routine care.\n* Estimated glomerular filtration rate greater than 15 ml\u002Fmin\u002F1.73m2 (except for participants with a renal transplant commenced on tacrolimus, who may be included regardless of eGFR, provided they are not on dialysis)..eGFR result obtained at screening or within the last 6 months or patients record confirming history of CKD 5.\n* Participants on any form of dialysis.\n* Participant with advanced liver failure (stage Child-Pugh C).\n* Participants with liver transplant.\n* Participants with allogeneic haematopoietic stem cell transplant.\n* Participants previously enrolled in the PHOENIX trial.\n* Participant who has declined participation and has declined reapproach for subsequent drugs.\n* Index drug exceeding trial drug cap.\n\nRe-approach Criteria: Previously declined patients will only be re-approached in subsequent admissions six-months after the first approach.\n\n\\* We wish to ensure that no more than 20% of participants are included on the basis of any single index drug. The numbers recruited on each index drug will be monitored and recruitment on specific drugs may be limited, or paused, at times throughout the study. This process will be administered by the Trial Management group, and monitored by the Trial Steering Committee.",{"count":109,"type":23},2000,[26],"It is known that individuals respond differently to the same medicine with some people benefitting, some experiencing no effect and others suffering side-effects or even coming to harm. Some of the differences in response to medications can be explained by our genes. Genes are short sections of DNA. Each individual has over 20,000 different genes. Genes carry instructions for making the proteins needed to build things within the body including the sites where medicines act. Pharmacogenomics is the study of how our genes affect the way our body responds to medications.\n\nDoctors can test for gene variations that might put an individual at risk of severe side-effects or mean that they are likely to receive no benefit from a specific medicine. Though not widely available in the NHS, testing allows doctors and patients to chose a different dose or avoid the medicine completely. It is estimated that almost everyone in the population (\\>95%) carries at least one gene variation that affects our response to medicines.\n\nThe PHOENIX study will recruit 4,000 participants who are admitted to hospital or attend an outpatient clinic who require a new drug prescription. The new drug prescription will be one who known pharmacogenomic implications. A cheek (buccal) swab will be taken which can be used to test a large number of genes known to alter the response to medicines. Around half of the participants will be tested immediately whilst the other half will have the test after three months. The results of the test relevant to each patients new prescription will enable the doctor prescribing to determine if any changes to that medicine would be beneficial. Information will be collected about participants quality of life, subsequent admissions to hospital, medication changes and side-effects. An assessment of cost saving to the NHS will also be made.",[113],"Pharmacogenomic Drug Interaction",[115,116,117,118,119,120],"Gene-drug","Gene panel","Polypharmacy","Adverse drug reaction","Health economics","pharmacogenomics","2026-04-20",{"date":123,"type":34},"2026-04-21",{"date":125,"type":34},"2025-04-09",{"date":127,"type":23},"2026-09-30",{"name":40,"class":41},5,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":24,"phases":140,"briefSummary":141,"conditions":142,"keywords":153,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},"100414271","icormica---stratified-medicine-in-angina-100414271","NCT04674449","iCorMicA - Stratified Medicine in Angina","International Study of Coronary Microvascular Angina (iCorMicA): a Randomised, Controlled, Multicentre Trial and Registry","iCorMicA","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. A clinical plan for invasive coronary angiography.\n3. Symptoms of angina (typical or atypical) according to the Rose- and\u002For Seattle Angina questionnaires.\n4. Able to comply with study procedures.\n5. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure).\n2. History of coronary artery bypass surgery.\n3. Presence of obstructive disease evident in a main coronary artery (diameter \\>2.5 mm), i.e. a coronary stenosis \\>50% and\u002For a fractional flow reserve (FFR) ≤0.80\\*.\n4. Logistical reason\\*. \\*These patients will enter a follow-up registry.",{"count":139,"type":23},1500,[26],"The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.",[143,144,145,146,147,148,149,150,151,152],"Microvascular Angina","Angina, Stable","Ischemia With No Obstructive Coronary Arteries (INOCA)","Coronary Microvascular Dysfunction (CMD)","Ischaemic Heart Disease","Non-Obstructive Coronary Atherosclerosis","Coronary Artery Disease","Vasospastic Angina","Coronary; Ischemic","Angina Attacks",[154,155,156,157,158,159,160,161],"angina","microvascular angina","ischaemia with no obstructive coronary artery disease (INOCA)","stratified medicine","clinical trial","outcomes research","prognosis","health economics","2026-04-03",{"date":164,"type":34},"2026-04-09",{"date":166,"type":34},"2020-12-30",{"date":168,"type":23},"2030-12-31",{"name":40,"class":41},39,{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":24,"phases":180,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":7},"100453052","phase-3-early-vasopressors-in-sepsis-100453052","NCT05179499","Early Vasopressors in Sepsis","EVIS","Inclusion Criteria:\n\n* Age \\>18 years\n* Clinically suspected or proven infection resulting in principal reason for acute illness\n* SBP \\\u003C 90 mmHg or MAP of \\\u003C 65 mmHg (within an hour of eligibility assessment)\n* Measured serum lactate of \\> 2 mmol\u002FL. The serum lactate should be measured 2 hours prior to determination of eligibility, where possible. Longer timeframes may be used and justified within the medical notes if, in the opinion of the investigator, the clinical status of the patient has not significantly improved in the time interval between lactate measurement and eligibility assessment. Lactate measurements more than 4 hours prior to eligibility assessment should not normally be used.\n* Hospital presentation within last 12 hours\n\nExclusion Criteria:\n\n* \\>1500ml of intravenous fluid prior to screening\n* Clinically judged to require immediate surgery (within one hour of eligibility assessment)\n* Immediate (\\\u003C 1 hour) requirement for central venous access\n* Chronic renal replacement therapy\n* Known allergy\u002Fadverse reaction to norepinephrine\n* Palliation \u002F end of life care (explicit decision by patient\u002Ffamily\u002Fcarer in conjunction with clinical team that active treatment beyond symptomatic relief is not appropriate)\n* Previous recruitment in the trial\n* Patients with permanent incapacity\n* Pregnancy. All women of childbearing potential (WoCBP) must have a negative urine or serum pregnancy test result completed as part of screening requirements.\n\nWoCBP are defined as fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.\n\n* Other primary causes of shock (e.g. suspected cardiogenic shock, haemorrhagic shock, etc)\n* History or evidence of any other medical, neurological or psychological condition that would expose the subject to an undue risk of a significant Adverse Effect as determined by the clinical judgement of the investigator\n* Participation in other clinical trials of investigational medicinal products",{"count":179,"type":23},1006,[181],"PHASE3","Sepsis is a life-threatening reaction to an infection. It happens when the immune system overreacts to an infection and starts to damage the body's tissues and organs.\n\nThe aim of this research study is to compare the two different ways to treat sepsis, in the early phase of treatment immediately after the participants arrive in hospital. The standard approach is to give a salt solution fluid through a drip in the participants arm to start with, then adding in a medication that increases the blood flow to the participants vital organs (a vasopressor mediation called norepinephrine) if required. The alternative approach is to start the vasopressor medication immediately, and then add in extra salt solution fluid via a drip if required. Vasopressors work by increasing the blood pressure which allows a better blood flow to the internal organs. The investigators plan to see which approach is better and to see if they have a role in improving a patient's recovery time, reducing complications, the length of time they stay in hospital and longer term poor health.\n\nBased on research that has already been done, the investigators believe treating patients with vasopressors when they arrive in the Emergency Department, may have potential advantages over the standard fluids used today. However, the evidence is not clear and that is why this research is being done.",[184],"Sepsis",[184,186,187,188,189,190],"Resuscitation","Norepinephrine","Intravenous fluids","Emergency Medicine","Critical Care","2026-02-10",{"date":193,"type":34},"2026-02-12",{"date":195,"type":34},"2022-10-11",{"date":197,"type":23},"2027-10",{"name":40,"class":41},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":79,"enrollmentInfo":206,"targetDuration":4,"studyType":24,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":42},"100623996","rewiring-the-brain-immune-axis-for-chronic-pain-using-transcranial-magnetic-stimulation-in-psoriatic-arthritis-100623996","NCT07403890","Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis","REACT","Inclusion Criteria:\n\n* Adults ≥ 18 years ≤ 75 years\n* Diagnosis of PsA according to CASPAR (Classification Criteria for Psoriatic Arthritis).\n* Low disease activity (no more than one joint with clinically active swelling) or remission\n* Chronic pain for at least 3 months and VAS (Visual Analogue Scale) pain ≥30 mm\n* Stable treatment ≥3 months prior to entering the study\n* Able and willing to maintain medication for the duration study\n* Able to undergo MRI and TMS procedures\n\nExclusion Criteria:\n\n* Inability to provide written informed consent.\n* Severe physical impairment (e.g. blindness, deafness, paraplegia) Pregnant, planning pregnancy or breast feeding.\n* Severe claustrophobia precluding MRI.\n* Contraindications to MRI (e.g. metal implants\u002F pacemaker).\n* Contraindications to TMS (e.g. history of seizures).\n* Serious infection including sepsis, tuberculosis and opportunistic infections such as invasive fungal infections.\n* Major confounding neurological disease including Multiple\n* Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, Alzheimer's Disease",{"count":207,"type":23},40,[26],"Despite advances in immunomodulatory therapies, many Psoriatic arthritis (PsA) patients experience persistent pain unrelated to clinical active joint inflammation. Recent evidence suggests the Inferior Parietal Lobule (IPL) serves as a neuroimmune hub linking central neural activity with peripheral immune dysregulation. In a prior feasibility study, a single L-IPL-targeted TMS session reduced pain and altered immune signalling in inflammatory arthritis by reducing STAT3 phosphorylation in circulating monocytes. This study builds on those findings by evaluating whether rTMS over 4 weeks can induce sustained immune reprogramming while providing meaningful pain relief.",[88],"NOT_YET_RECRUITING","2026-02-04",{"date":214,"type":34},"2026-02-11",{"date":216,"type":23},"2026-03-01",{"date":218,"type":23},"2028-03-28",{"name":40,"class":41},{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":24,"phases":230,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":42},"100608948","early-phase-1-tescs-for-upper-limb-rehab-in-spinal-cord-injury-100608948","NCT07208188","tESCS for Upper Limb Rehab in Spinal Cord Injury","Transcutaneous Spinal Cord Stimulation for Rehabilitation of Upper Limbs in Early Spinal Cord Injury: Randomised Feasibility Study","SCIRUS","Inclusion Criteria:\n\n* Aged 18 years or over, both sexes.\n* At least 6 weeks post-implant (in participants having a surgery for an implant to stabilise the spine).\n* ISNCSCI upper extremity motor score between 5 and 30 (both arms\u002Fhands)\n* GRASSP-strength score \\>=15 \\& \\\u003C70\n* Medically stable, cognitively intact and able to breathe independently.\n* Attending upper limb therapy sessions at the QENSIU\n* Planned stay longer than the duration of the intervention\n* Able to sit for more than 2 hours a day\n\nExclusion Criteria:\n\n* Unstable cervical spine injury\n* Needing ventilation assistance during daytime\n* Any implanted active metallic device without unconfirmed MRI compatibility (in our previous studies, we safely applied tESCS to participants with MRI-compatible devices\u002Fimplants)\n* Pregnancy and\u002For lactation.\n* Non-injury-related neurological impairment\n* Severe spasticity which have been unstable prior to enrolment\n* Botulinum toxin injections-\n* Clinically significant severe depression\n* Patients who have cardiovascular disease\n* Patients with severe ongoing Autonomic Dysreflexia\n* Skin conditions or allergies that may affect electrode placement.\n* Current infections\n* Patients who have been involved in any other interventional study",{"count":229,"type":23},20,[231],"EARLY_PHASE1","Regaining hand and arm function is an important step towards regaining independence following high-level spinal cord injury (tetraplegia). The delivery of small electrical pulses over the skin above the spinal cord, called transcutaneous spinal cord stimulation (tESCS), appears to improve the arm and hand function of people who have had tetraplegia for several years when delivered at the same time as upper limb therapy. However, tESCS has not been tested in people who have a new spinal cord injury. It should be straightforward to deliver tESCS during standard upper limb therapy sessions to inpatients receiving primary rehabilitation. The investigators want to test the practical aspects of delivering this intervention and also to compare recovery between a group of people who only receive upper limb therapy and a group who receive upper limb therapy and tESCS. If successful, tESCS could in the future be used as part of regular therapy following an acute spinal cord injury. Benefits could include faster and better recovery, reduced stay in hospital, and reduced NHS costs.",[234],"Spinal Cord Injuries (SCI)",[236,237,238,239,240],"Tetraplegia","incomplete","subacute","transcutaneous spinal cord stimulation","randmised feasibility study","2025-09-26",{"date":243,"type":34},"2025-10-06",{"date":245,"type":23},"2025-11",{"date":247,"type":23},"2027-12",{"name":40,"class":41},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":257,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":24,"phases":260,"briefSummary":262,"conditions":263,"keywords":267,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":42},"100596647","phase-2-sarcoma-surgery-wound-complications-comparing-usual-versus-negative-pressure-dressing-100596647","NCT07048184","Sarcoma Surgery Wound Complications Comparing Usual Versus Negative Pressure Dressing","Sarcoma Surgery Wound Complications Comparing Usual Versus Negative Pressure Dressing: a Randomised Phase II Trial","SUNDIAL","Inclusion Criteria:\n\n* Sarcoma of the upper\u002Flower limb or torso requiring wide local excision, planned marginal excision or amputation\n* Able to provide informed consent\n* Aged 16 years or over\n* Able, and willing, to adhere to scheduled trial procedures and visit schedule\n\nExclusion Criteria:\n\n* Previous surgery to planned surgical field\n* Contra-indication to surgical excision of the tumour\n* Disseminated malignancy on pre-op radiological imaging\n* Post-radiation sarcoma\n* Allergy to adhesive dressing\n* Subjects who, in the opinion of the PI, will be unable to comply with follow-up","16 Years",{"count":259,"type":23},94,[261],"PHASE2","To compare the differences in clinical outcomes and health economics between standard absorbent dressings versus Negative Pressure Wound Therapy dressings following the surgical resection of sarcoma tumours.",[264,265,266],"Sarcoma","Negative Pressure Therapy","Wound Complication",[264,268,266,269,270,271,272],"Surgery","Negative Pressure Wound Therapy","NPWT","Dressing","Tumour Resection","2025-07-04",{"date":275,"type":34},"2025-07-09",{"date":277,"type":23},"2025-12-01",{"date":279,"type":23},"2027-09-30",{"name":40,"class":41},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":24,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":42},"100414537","trabecular-metal-economic-and-clinical-knee-trial-100414537","NCT04677907","TRabecular Metal Economic and Clinical Knee Trial","Health Economic and Clinical Comparison of Trabecular Metal Uncemented and Cemented Modular Total Knee Replacements - A Double Blinded Randomised Controlled Trial","TRECK","Inclusion Criteria:\n\n* Male or female subjects may be recruited to the evaluation.\n* Age - there are no restrictions relating to age of the patient.\n* Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.\n* Subjects who in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigation procedures and are willing to return to the hospital for all the required post-operative follow-ups.\n* Subjects with uni-lateral osteoarthritis of the knee or subjects with bi-lateral osteoarthritis of the knee, who have a well functioning and pain free knee replacement in the contralateral knee.\n* Subjects who require a TKR for surgical management of osteoarthritis\n\nExclusion Criteria:\n\n* Patients who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in the study.\n* Patients with bi-lateral disease that significantly impacts on their current function and pain.\n* Patients who require revision knee arthroplasty surgery.\n* Disorders of the feet, ankles, hips or spine causing significant abnormal gait or significant pain.\n* Neurological conditions affecting movement.\n* Patients with a pathology, which, in the opinion of the Chief Investigator, will adversely affect healing.\n* Patients with other disorders which, in the opinion of the Chief Investigator, will\u002Fcould impair rehabilitation.\n* Subjects who in the opinion of the study investigator are unlikely to comply with the study follow-up protocol",{"count":290,"type":23},144,[26],"To compare the differences, if any, in clinical outcome, patient satisfaction and survivorship between cemented and uncemented Total Knee Replacements (TKR)? To investigate if there are health economic implications of using uncemented TKRs in the NHS?",[294,295],"Total Knee Replacement","Orthopedics",[297,295,298,299,300],"Total Knee Replacements","Orthopedic devices","Arthroplasty","Uncemented","2025-06-20",{"date":303,"type":34},"2025-06-25",{"date":305,"type":34},"2022-05-10",{"date":307,"type":23},"2035-06-30",{"name":40,"class":41},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":20,"enrollmentInfo":316,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":42},"100576564","evaluating-the-role-of-il-17-as-an-orchestrator-of-peripheral-central-cross-talk-in-depressive-symptoms-100576564","NCT06786936","Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms","ELATE","Inclusion Criteria:\n\n* Adults ≥18 years \\\u003C 75years\n* Diagnosis of PsO or PsA, made by a dermatologist or rheumatologist.\n* Selected to start secukinumab\u002F bimekizumab\u002F Ixekizumab as part of their standard clinical care by their usual dermatology team for PsO or rheumatology clinical team for PsA in line with the license for secukinumab\u002F bimekizumab\u002F Ixekizumab and NICE\u002FSMC criteria.\n* No contraindications to MRI (for example metal fragments or implantable devices not compatible with MRI. (no extra x-ray images will be obtained to check placement of metal fragments or clips insitu. Existing images may be used to check for possible contraindications)\n* Satisfactory completion of standard pre-biologic safety screening (including, but not limited to, exclusion of latent TB infection according to local protocol, chest X-ray, negative HIV screen, negative Hepatitis screen antibody, negative Hepatitis B surface antigen \\[Hep B sAg\\] and negative Hepatitis B anti-core antibody \\[Hep B cAb\\])\n* Recent (but not within 4 weeks prior baseline) use of intra-muscular or intra-articular steroid injections\n* Women of Child-Bearing Potential (WoCBP) must be willing to use effective contraception for study duration. Further information is provided in appendix 1.\n* Willing to participate and give informed consent\n\nExclusion Criteria:\n\n* Inability to provide written informed consent\n* Severe physical impairment (e.g., blindness, deafness, paraplegia).\n* Clinically important, active infections e.g. active TB\n* History of inflammatory bowel disease\n* Pregnant or breast feeding\n* Severe claustrophobia precluding MRI\n* Contraindications to 7T MRI (metal implants in the ears, head or neck, microbladed\u002F tattooed eyebrows, metal fragments in the eyes)\n* Confounding neurological disease including MS, Stroke, Traumatic Brain Injury\n* Previous exposure to IL-17A, IL-17A\u002FF, IL-17R inhibitors or IL-23 p19\u002Fp40 inhibitors in the last 6 months\n* Hypersensitivity to any of the excipients in secukinumab\u002F bimekizumab\u002F ixekizumab.\n* Any reason which, at the investigator's discretion, would make them unsuitable to take part in the study.",{"count":317,"type":23},50,"OBSERVATIONAL","The investigators seek clinically actionable understanding of the mechanisms that underlie depression in the context of immune mediated inflammatory diseases (IMIDs), delivered by a focused immune intervention study examining brain circuitry using state of the art imaging in the context of exquisitely specific therapeutic immune interception in human immune disease.\n\nGlutamate concentration in the NAcc will be positively correlated with the magnitude of the inflammatory response and will be attenuated by IL-17A inhibition. Ultimately, this will be associated with an improvement in depressive symptoms.\n\nThe strength of coupling between early and late systems will be attenuated in the context of IL-17A-driven inflammation and will be correlated with less frequent switching behaviour following negative outcomes and ultimately depressive symptoms. This coupling will be re-established following IL-17 antagonism.\n\nPatients whose depressive symptoms benefit most from IL-17A antagonism will exhibit greatest resting-state and task-specific functional connectivity between Th-NAcc.",[88,321,322],"Depression","Psoriatic Plaque","2025-06-18",{"date":325,"type":34},"2025-06-19",{"date":327,"type":34},"2025-06-02",{"date":329,"type":23},"2027-04-30",{"name":40,"class":41},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":79,"enrollmentInfo":339,"targetDuration":4,"studyType":24,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":42},"100534551","neurofeedback-for-nociplastic-pain-in-rheumatoid-arthritis-nectar-100534551","NCT06240299","Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR)","Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis","NECTAR","Inclusion Criteria:\n\n* Fulfilment of the ACR\u002FEULAR Classification Criteria for rheumatoid arthritis (RA)\n* Fulfilment of the American College of Rheumatology criteria for chronic widespread pain\n* Stable disease (swollen joint count ≤1 and CRP ≤10)\n* Has normal or corrected to normal vision and hearing abilities\n* Right-handed (to reduce baseline motor response test heterogeneity)\n* Pain intensity equal or larger than 4 on the Visual Numerical Scale (0 no pain, 10, max pain imaginable)\n\nExclusion Criteria:\n\n* Unable to understand the task.\n* Unable to provide a written informed consent.\n* Unable to understand English.\n* Major confounding neurological diseases including Multiple Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, and Alzheimer's Disease)\n* Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in the study (psychosis, suicidal ideation etc)\n* Under active management of pain team (changing medications, other non pharmacological pain treatment)\n* Involved in other interventional experimental studies",{"count":340,"type":23},16,[26],"Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Published literature shows that fibromyalgia can be treated by neurofeedback, a noninvasive method that is based on the voluntary modulation of cortical activity. In this pilot study, the investigators want to test the effect of neurofeedback on the fibromyalgia component of pain in rheumatoid arthritis, and also to investigate its effects on related symptoms such as fatigue and sleep disturbance.",[344,345],"Rheumatoid Arthritis","Chronic Widespread Pain","2025-06-11",{"date":348,"type":34},"2025-06-15",{"date":350,"type":34},"2024-06-24",{"date":352,"type":23},"2027-01-29",{"name":40,"class":41},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":363,"conditions":364,"keywords":368,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":4},"100590791","peri-operative-surgical-care-optimisation-for-patients-requiring-emergency-surgery-100590791","NCT06972017","Peri-Operative Surgical Care Optimisation for Patients Requiring Emergency Surgery","PERI-SCOPES","Group 1 and 2: EmLap and NoLap patients (up to 30 participants)\n\nPatient inclusion\u002Fexclusion criteria should mirror NELA inclusion\u002Fexclusion criteria and NELA NoLap guidelines. NELA is the \"National Emergency Laparotomy Audit\" which recruits patients in Wales and England and there inclusion\u002Fexclusion criteria are widely accepted for use in Emergency General Surgery research.\n\nInclusion criteria\n\n* Age \\>65 years old\n* Able to communicate in English\n* Cognitively able to complete the survey\u002Finterviews\n* Able to provide informed, voluntary consent\n* First line treatment is expedited, urgent or emergency abdominal surgery on the gastrointestinal tract\n* Surgery can be laparoscopic or open approach\n\nExclusion criteria\n\n* Age \\\u003C65 years old\n* NoLaps should be excluded if management involved interventional radiology or endoscopic procedures\n* Patients who are offered a period of conservative treatment are not automatically NoLap if surgery may ultimately be offered\n* Diagnosis of dementia or long-standing cognitive impairment\n* Elective laparotomy\u002Flaparoscopy\n* Diagnostic laparotomy\u002Flaparoscopy where no subsequent procedure is performed (however, if no procedure is performed because of inoperable pathology, then include)\n* All surgery involving the appendix or gallbladder, including any surgery relating to complications\n* Non-elective hernia repair without bowel resection or division of adhesions\n* Non-elective formation of colostomy or ileostomy\n* Trauma surgery (blunt or penetrating), vascular surgery, obstetric\u002Fgynaecological surgery or transplant surgery\n* Surgery for pathology of oesophagus, spleen, renal tract, kidneys, liver, gallbladder and biliary tree, pancreas or urinary tract\n\nGroup 3: Families\u002FSupporters (up to 30 participants) Inclusion criteria\n\n* Identified by the patient participant (only approached if nominated by patient)\n* Age \\>18 years old\n* Able to communicate in English\n* Cognitively able to complete the survey\u002Finterviews\n* Able to provide informed, voluntary consent\n\nExclusion criteria\n\n* Age\\\u003C18 years old\n* Lack of patient consent to family\u002Fsupporter involvement\n\nGroup 3: Consultants (interview:12-20 participants\u002Fsurvey: minimum 52 participants) Inclusion criteria\n\n* Key decision-makers will be identified in workstream 1 (likely: surgeons, intensivists and anaesthetists)\n* Post-CCT (Certificate of Completion of Training)\n* Participate in active on-call for EGS in a UK-based Hospital where they make decisions in EGS regularly\n\nExclusion criteria\n\n• Consultants not done \\>2 years of on-call",{"count":362,"type":23},112,"Emergency General Surgery (EGS) is an umbrella term which describes all patients presenting to hospital with an acute abdominal problem. Patients can have various conditions requiring emergency operations. EGS is one of the most common reasons for an emergency admission in the UK.\n\nEGS is often referred to as \"high-risk\" surgery. For those patients who do survive after their surgery, many struggle with frailty and new medical problems resulting in a reduction in their quality of life (QoL).\n\nThe goal of this observational study is to explore QoL and decision-making in EGS through questionnaires and interviews with patients, families\u002Fsupporters and consultants working in EGS.\n\nWorkstream 1 will involve patients and families\u002Fsupporters. Workstream 2 will involve consultants.\n\nThe investigators are interested in patients who have either undergone EGS (EmLaps) or have needed but not undergone EGS (NoLaps). The investigators are interested in exploring participants (patients, families\u002Fsupporters and consultants) experiences of this EmLap vs NoLap decision.\n\nThe main questions the investigators want to answer are:\n\n* What is the long-term QOL of EmLap\u002FNoLap patients and their family\u002Fsupporters?\n* How do patients and their family\u002Fsupporters describe their experience of decision-making in EGS?\n* What are consultant's experiences and views on decision-making in EGS?\n\nWorkstream 1 participants (patients and family members\u002Fsupporters) will complete questionnaires and take part in interviews at different time-points following their decision (1 month\u002F3 months\u002F 9-12 months). Questionnaires and interviews will explore QoL and decision-making in EGS.\n\nConsultant participants will be asked to complete an online survey and\u002For take part in an individual interview. Both will explore decision-making in EGS.",[365,366,367],"Quality of Life (QOL)","Decision Making","Emergency General Surgery",[369,370,371,372,367],"Quality of Life","Decision-making","NoLap","EmLap","2025-05-06",{"date":375,"type":34},"2025-05-14",{"date":377,"type":23},"2025-06",{"date":247,"type":23},{"name":40,"class":41},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":42},"100579211","phase-2-nano2-in-large-vessel-occlusion-stroke-novel-100579211","NCT06821347","NanO2 in Large VessEL Occlusion Stroke (NOVEL)","NanO2 in Large VessEL Occlusion Stroke (NOVEL): a Multicentre Single-blind, Randomised, Placebo-controlled Blinded Biomarker End-point Clinical Trial of Perfluorocarbon in Acute Ischaemic Stroke Due to Large Vessel Occlusion","NOVEL","Inclusion Criteria:\n\n1. Male or non-pregnant female aged ≥ 18 years\n2. Acute ischemic stroke fulfilling perfusion imaging criteria (ischemic core volume \\\u003C 70 mL, mismatch ratio \\> 1.8 and mismatch volume \\> 15 mL using RAPID or equivalent CE-marked software)\n3. Eligible for thrombolysis or thrombectomy\n4. Intracranial LVO on CTA (occlusion of the terminal ICA, MCA-M1, ≥1 proximal MCA-M2, or proximal posterior cerebral artery (PCA-P1))\n5. ≤ 9 hours after last known well (if waking with symptoms, last known well time is calculated as the mid-point between going to sleep and waking)\n6. Pre-stroke functional independence (estimated pre-stroke mRS ≤2)\n7. NIHSS score ≥ 6 (or NIHSS ≥ 2 if PCA-P1 occlusion) at randomisation\n\nExclusion Criteria:\n\n1. History of significantly impaired renal eGFR (\\\u003C30ml\u002Fmin) or hepatic function (transaminases \\>3 times upper limit of normal or history of cirrhosis), unstable angina or heart failure (NYHA 3 or 4).\n2. Pre-existing lung disease requiring supplemental chronic or intermittent oxygen therapy (NB oxygen therapy given post-stroke is not an exclusion)\n3. Previous hypersensitivity reaction to NanO2 excipients and\u002For compounds similar to NanO2\n4. Pregnancy (for women of child-bearing potential a negative pregnancy test will be required prior to randomisation) or breast feeding women.\n\n   Women of child-bearing potential is defined as experienced menarche; AND not undergone successful surgical sterilisation (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy); AND not post-menopausal i.e. amenorrhea for ≥12 consecutive months (without another medical cause)\n5. Participation in another CTIMP within preceding 90 days or 5 half-lives of the investigational product, whichever is longer, or previous participation in NOVEL.",{"count":389,"type":23},172,[261],"This is a National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) clinical trial aiming to investigate a possible new treatment to limit damage to the brain caused by a stroke. Strokes that are caused by a clot blocking an artery in the brain ('ischaemic' strokes) starve brain tissue of oxygen and nutrients. Over a short period of time without oxygen, this tissue becomes permanently damaged. The trial aims to investigate the effects of a drug that carries extra oxygen, called NanO2, on the amount of brain tissue damage. By carrying extra oxygen to brain tissue NanO2 may allow the tissue to survive for longer. It might be especially useful to prevent further damage happening while treatments to try and open the blocked blood vessel are given. Treatments may include 'clot-busting' drugs, or procedures to physically open a blocked artery. These treatments are very effective, but take time to successfully open the blockage. The study will involve treating people as early as possible after the stroke, and comparing brain scans before and after treatment. Patients diagnosed with a stroke that has occurred within the past 9 hours will be eligible to participate. The study will involve 8-15 hospitals across the UK. Participation in the study will last approximately 90 days. The majority of the study assessments will be during the first 5 days during inpatient hospital stay. There will be a telephone follow-up at 30 days and 90 days post-discharge.",[393],"Stroke Acute",[395,396,397],"acute ischaemic stroke","large vessel occlusion","thrombolysis","2025-04-01",{"date":400,"type":34},"2025-04-04",{"date":402,"type":23},"2025-05-01",{"date":404,"type":23},"2026-07-31",{"name":40,"class":41},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":24,"phases":414,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":4},"100581548","behavioural-activation-and-severe-learning-disabilities-100581548","NCT06851741","Behavioural Activation and Severe Learning Disabilities","Behavioural Activation for Depression in Adults with Severe Learning Disabilities. a Feasibility Randomised Controlled Study of Behavioural Activation with Treatment As Usual (TAU) Vs TAU Alone","Inclusion Criteria:\n\n* Administratively defined severe\u002Fprofound learning disabilities, confirmed by carer report using the Vineland Adaptive Behaviour Scales 3rd edition. A severe\u002Fprofound learning disability will be confirmed by an ABC composite score of 50 or below (Sparrow et al., 2016). Individuals with severe\u002Fprofound learning disabilities can be characterised by high support needs, limited or no expressive or receptive verbal communication, and significant impairments across adaptive functioning skills.\n* 18 years old and over\n* Clinically significant unipolar depression, meeting the Diagnostic Criteria for Psychiatric Disorders for use with Adults with Learning Disabilities\n* Has a family member or paid carer who has supported them for a minimum of 6 months to complete the screening and baseline visits OR is able to obtain information for the previous 4 months prior to randomisation. The carer, or another named individual, should be available for weekly-fortnightly treatment sessions with the practitioner, and should currently provide a minimum of 10 hours support per week to the participant.\n\nExclusion Criteria:\n\n* Mild\u002Fmoderate learning disabilities\n* A presentation judged by the research team as likely to interfere with the successful engagement with the intervention (e.g. severe agitation, late-stage dementia, uncontrolled epilepsy).",{"count":317,"type":23},[26],"Research shows that people with severe learning disabilities get depressed at least as often as the wider population. Psychological therapies are recommended to treat depression, and some of these have been adapted for those people with learning disabilities who can talk about their problems. No research has properly tested a psychological therapy for people with severe learning disabilities and any mental health problem. The investigators recently completed a study that tested a psychological therapy (behavioural activation) for people with mild learning disabilities and depression. Behavioural activation improves people's mood by helping them to re-engage in activity that has meaning and purpose for them, rather than relying on talking or thinking skills. Because of this behavioural activation might be promising for people with severe learning disabilities and depression. Along with PAMIS, an organisation for families of people with more profound disabilities, the investigators have adapted the therapy for this group. The investigators now want to find out if it would be possible to carry out a research project about whether behavioural activation works for depressed adults with severe learning disabilities. This is called a feasibility study. The investigators would see if it is possible to recruit 50 adults with severe learning disabilities, and if they are willing to be randomly placed in a group who get behavioural activation or a group who get usual help from services. Other information about running a study would be collected, including about keeping in contact with participants and what measures are needed to find out if change is happening.",[417,321],"Intellectual Disabilities",[419,321],"Intellectual disability","2025-02-26",{"date":422,"type":34},"2025-02-28",{"date":424,"type":23},"2025-03-04",{"date":426,"type":23},"2026-11-01",{"name":40,"class":41},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":435,"enrollmentInfo":436,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":4},"100579924","acute-concussion-management-in-emergency-medicine-with-7t-mri-a-feasibility-study-100579924","NCT06830616","Acute Concussion Management in Emergency Medicine with 7T MRI: a Feasibility Study","ACME-7T","Inclusion Criteria:\n\n1. Isolated head trauma\n2. Initial review within 96h of injury\n3. No acute findings on CT head\n4. Aged 18-40 years\n\nExclusion Criteria:\n\n1. Patient unable to give informed consent\n2. Patient unable to speak and understand English\n3. Patients where alternative diagnosis cannot be excluded\n4. Polytrauma\n5. Contra-indication to MRI\n6. BMI \\>40 or unable to comfortably lie on MRI scanner\n7. Pregnant\n8. Major confounding neurological disease e.g Multiple sclerosis, Stroke, Parkinson's Disease.\n9. Patient participation in other research studies concurrently","40 Years",{"count":229,"type":23},"The goal of this observational study is to learn about the brain imaging changes associated with concussion using a very detailed (7T) MRI scanner.\n\nTo do this, the investigators will study 7T MRI brain imaging in patients aged 18-40 who present to the Emergency Department within 96 hours of a head injury. Patients will be eligible if they have had a normal CT brain as part of their usual care.\n\nThe investigators will compare brain imaging from patients who have completely recovered from an episode of concussion to patients who still have significant symptoms at approximately 28 days after a head injury.\n\nThe study attempts to answer the following questions:\n\n1. Do patients with ongoing symptoms after concussion show greater 7T MRI brain imaging evidence of changes to the blood vessels at approximately 28 days after their injury in comparison to patients who have recovered fully?\n2. Do patients with ongoing symptoms after concussion show greater 7T MRI brain imaging evidence of changes in brain signaling pathways at approximately 28 days after their injury, in comparison to patients who have recovered fully?",[439],"Traumatic Brain Injury (TBI); Concussion, Initial Encounter",[441,442,443,444,445],"concussion","7T MRI","head injury","mildTBI","MRI brain","2025-02-18",{"date":448,"type":34},"2025-02-20",{"date":450,"type":23},"2025-02",{"date":245,"type":23},{"name":40,"class":41},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":42},"100579310","advances-in-imaging-to-assess-response-in-rectal-cancer-100579310","NCT06822634","Advances in Imaging to Assess Response in Rectal Cancer","Advances in Imaging to Assess Response in Rectal Cancer (AIR-REC)","AIR-REC","Inclusion Criteria:\n\n* Histologically confirmed rectal adenocarcinoma.\n* T stage 3b or above and\u002For high risk factors eg. EMVI, nodal disease.\n* Participant able to give written informed consent.\n* Male or non-pregnant female ≥18 years of age.\n* Scheduled to undergo radical radiotherapy.\n* Patients willing and able to comply with the protocol for the duration of study.\n\nExclusion Criteria:\n\n* Contra-indications to MRI, such as claustrophobia, excessive body weight, MRI unsafe implants, ferrous metal in the body, insufficient information on prior surgeries. MRI conditional implants where conditions cannot be met (e.g pacemakers).\n* Any previous radiotherapy to the pelvis.\n* Inflammatory bowel disease.\n* Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the study, as determined by the treating clinician.\n* History of physical or psychiatric disorder that would prevent informed consent and compliance with the protocol.\n* Patients with de-functioning stoma.\n* Major surgery within 28 days prior to trial entry.",{"count":229,"type":23},"The goal of this observational study is to determine the feasibility of acquiring serial MRI images for advanced radiotherapy planning in colorectal patients.\n\nThe main question it aims to answer:\n\nIs it feasible to acquire serial MR images for advanced radiotherapy planning for rectal cancer.",[464],"Colorectal Cancer (CRC)",[466,467,468,469],"Colorectal cancer","colorectal cancer (crc)","CRC","MRI","2025-02-11",{"date":472,"type":34},"2025-02-12",{"date":474,"type":34},"2024-11-11",{"date":476,"type":23},"2026-06-26",{"name":40,"class":41},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":4},"100576344","establishing-the-salience-of-type-1-interferon-pathway-blockade-in-the-central-mechanisms-of-sle-related-fatigue-100576344","NCT06784076","Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue","EPIC","Inclusion Criteria:\n\n* Adults ≥ 18 years \\\u003C 65 years\n* Fulfilment of the 2019 ACR (American College of Rheumatology)\u002FEULAR (European Alliance of Associations for Rheumatology) classification criteria for SLE\n* Persistent (\\>3 months) and clinically significant fatigue (≥6 on numerical rating 0-10 scale measuring average level of fatigue during the past 7 days)\n* Attainment of Lupus low disease activity state (LLDAS)\n\nExclusion Criteria:\n\n* Inability to provide informed written consent\n* Moderate or severe active SLE\n* Severe active CNS (Central Nervous System) Lupus and Lupus Nephritis\n* Contra-indications to anifrolumab\n* History of malignancy\n* History of recurrent infections or known risk factors for infection\n* Active or chronic infection\n* Concomitant biological therapies\n* Hypersensitivity to anifrolumab or excipients\n* Current treatment with a biologic medicine or monoclonal antibody (including B cell depleting therapies in the previous 52 weeks)\n* Previous exposure to anifrolumab\n* Contra-indications to MRI\n* Pregnant or breast-feeding\n* Females of child-bearing potential who do not agree to use an effective method of birth control until 12 weeks after the final study visit (See appendix 1).)\n* Severe physical impairment (e.g. blindness, paraplegia)\n* Medical or psychiatric conditions that in the judgement of the study personnel would preclude participation in the study","64 Years",{"count":229,"type":23},"Systemic Lupus Erythematosus (SLE) is a multi-system autoimmune disorder, characterised by activation of the interferon system. Of the multiple domains of this disease, patients identify fatigue as the most pervasive and disabling aspect. As many as 90% report significant levels of fatigue, a prevalence far in excess of that observed in the general population and most other chronic disorders. Moreover, its impact permeates all aspects of living as reflected by fatigue's strong relationship with impaired quality of life3 and work disability. Despite these substantial consequences, relatively little is known about this symptom and so the current dearth of accepted therapies is unsurprising. A better understanding of the underlying mechanisms of fatigue will be vital if efficacious interventions are to be developed in the future.\n\nThe investigators will recruit 25 SLE patients to achieve 20 full data sets. They will attend for a baseline 7T brain scan to primarily measure basal ganglia glutamate and then receive 5 months of a pharmacological blocker that antagonises type 1 interferon receptors before completing the study with a final 7T brain scan to undertake repeat measure of basal ganglia glutamate.",[489],"Systemic Lupus Erythematosus","2025-01-27",{"date":492,"type":34},"2025-01-29",{"date":494,"type":23},"2025-03-17",{"date":496,"type":23},"2027-03-15",{"name":40,"class":41},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":20,"enrollmentInfo":506,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":507,"conditions":508,"keywords":513,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":42},"100492823","7-tesla-mri-brain-imaging-to-decipher-filgotinibs-mode-of-analgesic-action-in-rheumatoid-arthritis-100492823","NCT05697159","7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis","Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis","TEMPO","Inclusion Criteria:\n\nPatients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are:\n\n* Adults ≥18 years \\\u003C 75 years.\n* Right-handed (to reduce neuroimaging heterogeneity).\n\nExclusion Criteria:\n\n* Inability to provide written informed consent.\n* Severe physical impairment (e.g. blindness, deafness, paraplegia).\n* Pregnant or breast feeding.\n* Severe claustrophobia precluding MRI.\n* Contraindications to MRI.\n* Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury.\n* Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.",{"count":229,"type":23},"This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients.\n\nThe investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate.\n\nThe second is related to peripheral inflammation, specifically joint synovitis, blood cytokines\u002Fchemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.",[344,509,510,511,512],"Sickness Behavior","Inflammatory Disease","Autoimmune","Pain, Chronic",[514,515],"Chronic pain","Rhuematoid arthritis","2025-01-13",{"date":518,"type":34},"2025-01-14",{"date":520,"type":34},"2023-08-22",{"date":522,"type":23},"2025-10-31",{"name":40,"class":41},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":532,"conditions":533,"keywords":537,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":546,"locationsCount":42},"100554855","scn1a-horizons-a-natural-history-study-of-scn1a-related-epilepsies-in-the-united-kingdom-100554855","NCT06504511","SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom","Patients meeting the following inclusion criteria will be considered eligible for this study:\n\n1. Patient and\u002For legally authorised representative must be willing and able to give informed consent\u002Fassent for participation in the study.\n2. Patient and parent\u002Fcaregiver are willing and able (in the Investigator's opinion) to comply with all study requirements (including ability and willingness to comply with virtual visits).\n3. Participant has a confirmed pathogenic (class 5) or likely pathogenic (class 4. SCN1A variant, as demonstrated by genetic testing.\n\nExclusion criteria:\n\nPatient has any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or may affect the patient's ability to participate in the study.",{"count":531,"type":23},400,"The aims of this prospective natural history study are to define the seizure, neuro-developmental, and behavioural characteristics of SCN1A-related epilepsies\u002FDravet syndrome in children and adults longitudinally over a period of three years. In addition, this study will compare missense and truncating genotypes in terms of i) rates of change of countable convulsive seizures per month and ii) neurodevelopmental outcome and trajectories.",[534,535,536],"SCN1A","Dravet Syndrome","Epilepsy",[536,534,538,539],"Natural History","Developmental Outcome","2024-07-15",{"date":542,"type":34},"2024-07-16",{"date":544,"type":34},"2023-11-20",{"date":66,"type":23},{"name":40,"class":41},{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":24,"phases":555,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":567},"100553876","extra-meso-exercise-therapy-in-mesothelioma-feasibility-100553876","NCT06491784","EXTRA-Meso (EXercise TheRApy in Mesothelioma) Feasibility","EXercise TheRApy in Mesothelioma - A Feasibility Study","Inclusion Criteria:\n\n1. Diagnosis of mesothelioma, ratified by a mesothelioma multi-disciplinary team (MDT) meeting\n2. Performance status 0 - 2\n3. Clinical frailty score ≤5\n4. Informed written consent\n\nExclusion Criteria:\n\n1. Performance status ≥3\n2. Clinical frailty score ≥6\n3. Unlikely to be able to participate in an exercise programme (clinician\u002Fphysiotherapist judgement)",{"count":207,"type":23},[26],"The goal of this clinical trial is to learn whether running an exercise study in patients with mesothelioma is feasible. The main question(s) it aims to answer are:\n\n1. Is it feasible to recruit patients to a randomised clinical trial of exercise therapy\n2. What are the barriers to study recruitment\n3. What are the barriers to study retention\n\nParticipants who decide to take part in the study will be randomly allocated one of two study arms:\n\n1. Standard of care, where the participant will undergo their usual clinical follow-up\n2. Exercise therapy, where the participant will receive a personalised 12 week exercise, nutrition and wellbeing programme Participants in both study arms will be asked to complete quality of life questionnaires and a basic fitness assessment at the start and end of the study follow-up period.\n\nParticipants will be asked if they would be happy to conduct a short interview with a member of the research team, to assess their views on the study. This interview will be audio recorded and the audio recording will be transcribed anonymously to allow researchers to improve future study design.",[558],"Mesothelioma","2024-07-03",{"date":561,"type":34},"2024-07-09",{"date":563,"type":34},"2024-01-25",{"date":565,"type":23},"2025-07-31",{"name":40,"class":41},2,{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":575,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":578,"conditions":579,"keywords":583,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":42},"100550376","biomarkers-in-scotland-cardiomyopathy-registry-bio-scotch-100550376","NCT06446271","Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)","Biomarkers in SCOTland CardiomyopatHy Registry","Inclusion Criteria:\n\n* Male or female ≥10 years of age\n* Written informed consent \u002F assent\n* Pathogenic or likely pathogenic variant in a cardiomyopathy gene (TTN, LMNA, MYBPC3, DSP, FLNC) or undergoing predictive genetic testing (if negative these people would be invited to enter the control arm)\n\nExclusion Criteria:\n\n* Unable to consent.\n* Geographical \u002F social reasons preventing attending study centre\n* Unable to complete study assessments.\n* Severe non-cardiac disease expected to reduce life expectancy \\\u003C 5 years\n* Current participation in a blinded drug interventional trial (or treatment within 4 weeks)","10 Years",{"count":577,"type":23},750,"Genetic cardiomyopathy is increasingly recognised and can lead to heart failure, arrhythmia and sudden cardiac death. Some gene positive patients have rapidly progressive disease with high rates of heart failure and cardiac transplantation, while others present with SCD. Other gene positive patients will never develop cardiomyopathy. At present, we cannot distinguish between these groups and rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging.\n\nThis study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.",[580,581,582],"Cardiomyopathies","Genetic Predisposition","Cardiomyopathy, Primary",[584,585,586],"Cardiomyopathy","Genetic","Biomarkers","2024-07-01",{"date":559,"type":34},{"date":590,"type":34},"2024-06-26",{"date":592,"type":23},"2027-03-19",{"name":40,"class":41},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":602,"sex":18,"minAge":257,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":24,"phases":605,"briefSummary":606,"conditions":607,"keywords":617,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":567},"100551493","axsend-exploring-immune-and-microbiota-effects-of-a-partial-enteral-nutrition-diet-in-axial-spondyloarthritis-100551493","NCT06460805","axSEND: Exploring Immune and Microbiota Effects of a Partial Enteral Nutrition Diet in Axial Spondyloarthritis","axSEND: Exploring Immune and Microbiota Effects of a Partial Enteral Nutrition Diet in People With Axial Spondyloarthritis","axSEND","Eligibility Criteria for Participants with axSpA\n\nInclusion criteria. Participants will fulfil ALL of the following:\n\n* Diagnosis of axSpA (fulfilling the ASAS criteria)\n* Active disease (BASDAI score ≥4) on day of study visit\n* Stable on treatment \\[defined as (1) no major change to therapy (change in treatment type) in the preceding 3 months AND (2) no minor change in therapy (adjustment of treatment dosage) in the preceding 1 month\\]\n* Age ≥ 16 years\n* Willing and able to give informed written consent.\n\nExclusion. Participants will have NONE of the following:\n\n* Pregnancy or breastfeeding\n* Prior diagnosis of IBD\n* Recipient of chemotherapy\u002Fimmunotherapy\u002Fradiotherapy in prior 3 months\n* Recent systemic antibiotic use (within last 1 month)\n* Current eating disorder\n* Food allergy incompatible with diet (e.g. cow's milk allergy)\n* Following a vegan diet\n* Major surgery in prior 3 months or planned in forthcoming 3 months.\n* Unable or unwilling to give informed consent\n* Unable or unwilling to try the PEN diet.\n\nEligibility Criteria for Healthy Volunteer Participants\n\nInclusion criteria. Participants will fulfil ALL of the following:\n\n* Age ≥ 16 years\n* Current student and\u002For staff member at the University of Glasgow\n* Willing and able to give informed written consent\n\nExclusion. Participants will have NONE of the following:\n\n* Pregnancy or breastfeeding\n* Prior diagnosis of an immune-mediated inflammatory condition\n* Recipient of chemotherapy\u002Fimmunotherapy\u002Fradiotherapy in prior 3 months\n* Recent systemic antibiotic use (within last 1 month)\n* Current eating disorder\n* Food allergy incompatible with diet (e.g. cow's milk allergy)\n* Following a vegan diet\n* Major surgery in prior 3 months or planned in forthcoming 3 months.\n* Unable or unwilling to give informed consent\n* Unable or unwilling to try the PEN diet.",true,{"count":604,"type":23},62,[26],"People with axial spondyloarthritis (axSpA) often have intestinal inflammation and intestinal microbiome dysbiosis, with some similarities to Crohn's-like inflammatory bowel disease (IBD) gut inflammation. However, research has not addressed whether Partial Enteral Nutrition (PEN), a diet formed of a liquid formula and some solid whole foods, which is effective at inducing remission in IBD, may influence the dysbiotic microbiome and inflamed, hyperpermeable intestine of axSpA patients, and whether these changes may be accompanied by alterations in systemic markers of inflammation. Thus, there is a need to determine the effects of PEN on these aspects in axSpA patients.\n\nIn this study, the investigators intend to trial a 2-week course (with optional additional 2-week extension) of a PEN diet in people with active axSpA disease. A group of healthy volunteers following the same diet will act as a control.",[608,609,610,611,612,613,614,615,616],"Axial Spondyloarthritis","Ankylosing Spondylitis","Inflammation","Dysbiosis","Arthritis","Spondylitis","Spondylarthritis","SpA","AxSpA",[618,619,620,621,622,623,624,625],"Partial Enteral Nutrition","Nutrition","Axial spondyloarthritis","Ankylosing spondylitis","axSpA","Diet","PEN","AS","2024-06-13",{"date":628,"type":34},"2024-06-14",{"date":630,"type":34},"2024-04-25",{"date":632,"type":23},"2025-08-01",{"name":40,"class":41},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":643,"conditions":644,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":567},"100551431","biomarkers-for-the-assessment-of-congestion-in-patients-with-ambulatory-and-hospitalised-heart-failure-100551431","NCT06459999","Biomarkers for the Assessment of Congestion in Patients With Ambulatory and Hospitalised Heart Failure","BIO-CONGEST","Inclusion Criteria:\n\n* Written informed consent.\n* Male or female ≥18 years of age.\n* Cohort A\n\n  * Meet European Society of Cardiology (ESC) criteria for diagnosis of HF1, including HF with reduced (HFrEF), mildly reduced (HFmrEF) and preserved ejection fractions (HFpEF).\n  * Hospitalised for the management of HF or outpatients.\n  * Undergoing clinically-indicated RHC or repeat clinically-indicated RHC.\n* Cohort B\n\n  * Meet ESC criteria for diagnosis of HFrEF.\n  * Undergoing implantation of CRT device and a simultaneous clinically-indicated RHC.\n* Cohort C\n\n  * Meet ESC criteria for diagnosis of HF, including HFrEF, HFmrEF, HFpEF.\n  * Requiring treatment with IV diuretics.\n\nExclusion Criteria:\n\n* Unwilling to consent.\n* Unable to consent to inclusion in study due to cognitive impairment.\n* Previously enrolled in the BIO-CONGEST study.\n* Current participation in a blinded drug interventional trial (or treatment within four weeks).\n* Pregnancy or breast-feeding (cohorts A + B where applicable).\n* Currently uncontrolled cardiac arrhythmia.\n* Severe aortic valvular disease.\n* Increased body mass index where satisfactory echocardiographic images are not possible.\n* Conditions that may confound congestion assessments in the opinion of the investigator, including: severe obstructive lung disease, severe fibrotic lung disease, severe liver disease, relevant active malignancy including lung cancer, pelvic cancer with caval compression, superior vena cava (SVC) obstruction syndrome, active viral or bacterial bronchopneumonia - chest x-ray (CXR) within four weeks showing consolidation, pulmonary contusion, pneumothorax, pneumonectomy, lobectomy, pulmonary embolism within the previous three months, indwelling intercostal chest drain, left ventricular assist device (LVAD), COVID-19 infection, type-1 acute myocardial infarction.",{"count":642,"type":23},140,"The goal of this study is to test the accuracy of new blood and urine tests in people with heart failure. The main question it aims to answer is:\n\n\\- Do new blood and urine tests correlate with fluid status? This will be determined by comparison to routine and gold-standard tests in a range of patients with heart failure.",[62,645],"Congestion","2024-06-10",{"date":628,"type":34},{"date":649,"type":23},"2024-06",{"date":651,"type":23},"2025-12",{"name":40,"class":41},{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":602,"sex":18,"minAge":659,"maxAge":257,"enrollmentInfo":660,"targetDuration":4,"studyType":318,"phases":4,"briefSummary":662,"conditions":663,"keywords":670,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":42},"100536929","the-gut-lung-axis-and-respiratory-illness-in-children-100536929","NCT06271213","The Gut-Lung Axis and Respiratory Illness in Children","Inclusion Criteria:\n\n* Any infant\u002Fchild\u002Fyoung person admitted to the RHC, Glasgow for an elective bronchoscopy or GI endoscopy.\n* Any infant\u002Fchild attending for an emergency\u002Felective orthopaedic operation without active respiratory or gastrointestinal conditions or receiving treatment for either condition. (Age range birth to 16 years for all groups recruited).\n* Any child attending respiratory department at RHC who can induce sputum and is having a blood sample taken, with latter part of standard of care.\n* Any infant\u002Fchild\u002Fyoung person admitted to RHC for a clinical care appointment with Asthma\u002Fwheeze before commencement of biologics therapy (treatment group).\n* Any child admitted to RHC with asthma\u002Fwheeze not indicated for biologic therapy (asthma control group).\n\nExclusion Criteria:\n\n* Use of antibiotics by the day of admission or have used antibiotics in the previous month (unless prophylactic antibiotics \\> 1 month use).\n* Any person 17 years old and above.\n* Any child known to be infected with, or at high risk of having had exposure to HIV, hepatitis B or hepatitis C viruses\n* . Any child and\u002For parent\u002Fguardian who cannot understand the English language where consent would be unethical.\n* Any child with Asthma currently receiving Biologics therapy (unless recruited via bronchoscopy route).","0 Years",{"count":661,"type":23},150,"The goal of this single-centre observational study conducted at the Royal Hospital for Children in Glasgow, Scotland, is to employ a multi-omics approach to investigate the \"gut-lung axis\" in health and disease.\n\nPart A is a cross-sectional study design investigating the postulated bidirectional link between the gut and lung microbiomes in children suffering from respiratory or gastrointestinal conditions. Children with no GI or respiratory issues attending for orthopaedic care will be used as a benchmark for a healthy gut-lung axis. The main questions we aim to answer are:\n\n* What does a healthy gut-lung axis look like?\n* Do children with respiratory issues show an altered gut microbiome?\n* Do children with GI issues show an altered lung microbiome?\n\nPart B is a longitudinal study design, that aims to assess the effects of biologics on the gut-lung axis by comparing the gut and lung microbiomes in children with asthma at two time-points who are indicated to start biologics therapy (Asthma treatment) or will not receive biologics therapy (asthma control).\n\nParticipants will provide:\n\n* airway samples (to investigate the lung microbiome)\n* blood samples (to assess inflammatory and metabolic factors which may mediate communication between the two sites) whilst under general anaesthetic for a treatment related to their standard of care\n* stool samples (to assess gut microbiome)\n* dietary information (food diary and\u002For food frequency questionnaire) to assess relationships between diet and the gut-lung axis.",[664,665,666,667,668,669],"Respiration Disorders","Respiratory Disease","Asthma in Children","Wheezing","Gastro-Intestinal Disorder","Healthy",[671,672,673,674],"Gut-Lung Axis","Microbiome","Multi-omics","Children","2024-02-14",{"date":677,"type":34},"2024-02-21",{"date":679,"type":34},"2024-02-04",{"date":681,"type":23},"2028-05-01",{"name":40,"class":41},""]